Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
103.38
-1.09 (-1.04%)
At close: Jun 26, 2026, 4:00 PM EDT
103.99
+0.61 (0.59%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Insmed Employees
Insmed had 1,664 employees as of December 31, 2025. The number of employees increased by 393 or 30.92% compared to the previous year.
Employees
1,664
Change (1Y)
393
Growth (1Y)
30.92%
Revenue / Employee
$492,526
Profits / Employee
-$711,391
Market Cap
22.41B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1,664 | 393 | 30.92% |
| Dec 31, 2024 | 1,271 | 359 | 39.36% |
| Dec 31, 2023 | 912 | 176 | 23.91% |
| Dec 31, 2022 | 736 | 123 | 20.07% |
| Dec 31, 2021 | 613 | 92 | 17.66% |
| Dec 31, 2020 | 521 | 86 | 19.77% |
| Dec 31, 2019 | 435 | 62 | 16.62% |
| Dec 31, 2018 | 373 | 159 | 74.30% |
| Dec 31, 2017 | 214 | 53 | 32.92% |
| Dec 31, 2016 | 161 | 36 | 28.80% |
| Dec 31, 2015 | 125 | 36 | 40.45% |
| Dec 31, 2014 | 89 | 28 | 45.90% |
| Dec 31, 2013 | 61 | 20 | 48.78% |
| Dec 31, 2012 | 41 | -1 | -2.38% |
| Dec 31, 2011 | 42 | 2 | 5.00% |
| Dec 31, 2010 | 40 | 25 | 166.67% |
| Dec 31, 2009 | 15 | -82 | -84.54% |
| Dec 31, 2008 | 97 | 3 | 3.19% |
| Dec 31, 2007 | 94 | -63 | -40.13% |
| Dec 31, 2006 | 157 | 72 | 84.71% |
| Dec 31, 2005 | 85 | 30 | 54.55% |
| Dec 31, 2004 | 55 | 35 | 175.00% |
| Dec 31, 2003 | 20 | -3 | -13.04% |
| Dec 31, 2002 | 23 | -37 | -61.67% |
| Dec 31, 2001 | 60 | 20 | 50.00% |
| Dec 31, 2000 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ascendis Pharma | 1,189 |
| Revolution Medicines | 883 |
INSM News
- 2 days ago - EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis - GlobeNewsWire
- 4 days ago - Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory - PRNewsWire
- 5 days ago - The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms - ETF Trends
- 12 days ago - Mizuho cuts Insmed target, sees buying opportunity after selloff - TheFly
- 18 days ago - Insmed Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 19 days ago - Insmed stock price decline a ‘buying opportunity’, says Roth Capital - TheFly
- 19 days ago - Insmed price target lowered to $179 from $180 at JPMorgan - TheFly
- 22 days ago - Insmed price target lowered to $195 from $205 at RBC Capital - TheFly